MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second quarter ended May 31, 2023, on Wednesday, July 12 at 8:30 a.m. EDT.
The call will be hosted by Mr. Paul Lévesque, President and Chief Executive Officer. Mr. Lévesque will joined be other members of the management team, including Chief Financial Officer, Mr. Philippe Dubuc, Chief Medical Officer, Dr. Christian Marsolais and Global Commercial Officer, Mr. John Leasure, who will be available to answer questions from participants following prepared remarks.
Participants are encouraged to join the call at least ten minutes in advance to secure access.
Conference call dial-in and replay information is below:
CONFERENCE CALL INFORMATION | |
Conference Call Date | July 12, 2023 |
Conference Call Time | 8:30 a.m. EDT |
Webcast link | https://edge.media-server.com/mmc/p/ot7rcxmr |
Dial in | 1-888-317-6003 (toll free) or 1-412-317-6061 (international) |
Access Code | 0616524 |
An archived webcast will also be available on the Company’s Investor Relations website under ‘Past Events’.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.
Contacts:
Investor inquiries:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-438-315-6608
Last Trade: | US$1.23 |
Daily Change: | 0.03 2.50 |
Daily Volume: | 24,471 |
Market Cap: | US$56.560M |
October 10, 2024 October 09, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB